← Back to Search

HU-Go App for Sickle Cell Disease Adherence

N/A
Waitlist Available
Led By Sherif M. Badawy, MD, MS
Research Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 12-21 years old
Any sickle cell disease genotype
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will look at how well young adults with sickle cell disease adhere to taking hydroxyurea, and how this affects their quality of life.

Who is the study for?
This trial is for young individuals aged 12-21 with any type of sickle cell disease who have been taking hydroxyurea consistently for at least 2 months. They must own or have access to a smartphone. Parents of eligible patients can also participate. Those recently hospitalized within the past week cannot join.
What is being tested?
The study is testing the 'HU-Go app' and its impact on medication adherence over time in adolescents and young adults with sickle cell disease. It aims to understand how using this app affects their health-related quality of life and habits related to taking hydroxyurea.
What are the potential side effects?
Since this trial involves an app, there are no direct medical side effects from interventions like drugs or surgery. However, participants may experience stress or frustration if they encounter technical issues with the app.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 12 and 21 years old.
Select...
I have a type of sickle cell disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Hydroxyurea adherence rate
Secondary study objectives
Adherence to Hydroxyurea using PROMIS Medication Adherence Scale (PMAS)
Hydroxyurea
Anxiety score using Patient reported outcomes measurement information system (PROMIS) measure
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: HU-Go app intervention armExperimental Treatment1 Intervention
Participants will use the HU-Go app intervention arm for 12 months.

Find a Location

Who is running the clinical trial?

Ann & Robert H Lurie Children's Hospital of ChicagoLead Sponsor
270 Previous Clinical Trials
5,182,032 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,938 Previous Clinical Trials
47,792,230 Total Patients Enrolled
Sherif M. Badawy, MD, MSPrincipal InvestigatorAnn & Robert H Lurie Children's Hospital of Chicago
2 Previous Clinical Trials
73 Total Patients Enrolled

Media Library

HU-Go app intervention arm Clinical Trial Eligibility Overview. Trial Name: NCT04691323 — N/A
Sickle Cell Disease Research Study Groups: HU-Go app intervention arm
Sickle Cell Disease Clinical Trial 2023: HU-Go app intervention arm Highlights & Side Effects. Trial Name: NCT04691323 — N/A
HU-Go app intervention arm 2023 Treatment Timeline for Medical Study. Trial Name: NCT04691323 — N/A
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top